Overview of cell lines profiled in this study
| Cell line name | Cancer type | Gene(s) | Amplification type | Monoclonal status | Source |
|---|---|---|---|---|---|
| PC3DM (mono) | Prostate | MYC | ecDNA | Yes | This study |
| PC3HSR (mono) | Prostate | MYC | HSR | Yes | This study |
| GBM39 (mono) | Glioblastoma | EGFRvIII | ecDNA | Yes | This study |
| COLO320-DM (mono) | Colorectal | MYC | ecDNA | Yes | This study |
| COLO320-DM | Colorectal | MYC | ecDNA | No | (Hung et al. 2021) |
| COLO320-DM | Colorectal | MYC | ecDNA | No | (Wu et al. 2019) |
| GBM39 | Glioblastoma | EGFRvIII | ecDNA | No | (Wu et al. 2019) |
| CHP-212 | Neuroblastoma | MYCN, TRIB2 | ecDNA | No | (Helmsauer et al. 2020) |
| COLO320-HSR | Colorectal | MYC | HSR | No | (Wu et al. 2019) |
| GBM39-HSR | Glioblastoma | EGFRvIII | HSR | No | (Wu et al. 2019) |
[i] Cell type name, cancer type, subset of important amplified oncogenes, amplification type, monoclonal status, and source. (HSR) Homogeneously staining region, (ecDNA) extrachromosomal DNA.